Detailed price information for Camp4 Therapeutics Corp (CAMP-Q) from The Globe and Mail including charting and trades.

Celcuity (CELC) is back in focus after reporting pivotal Phase 3 VIKTORIA-1 data for gedatolisib in HR-positive, HER2-negative advanced breast cancer, expanding the VIKTORIA-2 program and preparing ...

Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...

On Thursday, Celcuity Inc. CELC announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC) and Rubicon Organics (ROMJF) with bullish sentiments. According to TipRanks.com, McCammon ...

Q1 2026 call: gedatolisib FDA PDUFA July 17, ASCO VIKTORIA-1 data, VIKTORIA-2 expansion & cash runway—read now.

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its ...

MINNEAPOLIS - Celcuity Inc. (NASDAQ:CELC) reported a first-quarter loss of -$0.97 per share, beating analyst estimates of -$1.04 per share. The clinical-stage biotechnology company reported no revenue ...

Celcuity shares rose after the Phase 3 trial of a treatment for breast cancer was expanded to include endocrine-sensitive patients. Shares company rose 9.7% to $136.59 in late morning trading on ...

(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...

The average one-year price target for Celcuity (NasdaqCM:CELC) has been revised to $159.86 / share. This is an increase of 20 ...